Clinical trial
Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)
NCT07283692
Study timeline
Study start (actual)2026-03-01Date precision: day
Registry last updated2026-05-13
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Triple Negative Breast Cancerunresolved
Interventions
SerplulimabDRUG
PaclitaxelDRUG · verified · RxNorm: paclitaxel
CarboplatinDRUG · verified · RxNorm: carboplatin
Sponsors & collaborators
RenJi Hospitallead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT07283692 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.